NewAmsterdam Pharma (NAMS) stock

Metabolic therapies , market cap $2.3B

Oral therapies for metabolic diseases

Worth $2.3B

Pre-market

$18.91

+0.05%

Close $18.90 +0.05%

As of 9:05 AM ET pre-market, delayed 15+ min · Live for Pro members

Why is NAMS down?

Down 32% in 3 months, 14% under its 50-day average.

Down more than its industry: the 274 other stocks in it fell a median 15% over the same 3 months.

−2Long-term trend below a falling 200-day average, down over one year

Tell me next time NAMS moves

Free account, no card. An optional alert when NAMS moves or its score changes.

Or see it live, free until tomorrow morning. No account.

4 more things pulling NAMS's score down, for Pro members.

Quality Score

-3

Poor

In its industry

#188of 281

Biotech

Checks firing

2of 14

Trending down

From 52-week high

-55.2%

under its best in a year

NAMS's Quality Score rose 1 point on Fri, Nov 6, to -3. No cash flow figure on file.

Follow NAMS's trial news. Pro members can get an alert when NewAmsterdam Pharma files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NAMS files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“– Topline data from RUBENS Phase 3 expected by year-end 2026 –”Trial data · SEC filing · Aug 5

Cash$678M, about 18 quarters (4.5 years) at the last year's spendingOn Jun 30

Key facts on NAMS

Key facts on NAMS
Holding it back	Sales down 78% $102.7M → $22.5M in 3 years
Latest filing	8-K, Nov 4 Issued a release: "NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results"

1 more reason behind NAMS's -3, free with an account →4 more reasons behind NAMS's -3, for Pro members.

What's next

Mon Nov 9: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

Expected to report Wed Feb 17, before the open

After its last 4 reports it closed +4.7% on average, higher 3 of 4 times.

2 more dates ahead: conferences, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$678M, about 18 quarters (4.5 years) at the last year's spendingOn Jun 30

NAMS catalysts

Coming up

3 more coming up, with sizes and sources, for Pro members.

What's next for NAMS, and how long its cash lasts

Next step the company has named

End of 2026“– Topline data from RUBENS Phase 3 expected by year-end 2026 –”Trial data · SEC filing · Aug 5

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: PREVAILPhase 3 · Active · 9,541 people · main data estimated Nov 2026 · NCT05202509

5 more trials, 1 with data due this year, 2 more milestones and 51 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 18 quarters

$678M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Feb 28, 2025)
At-the-market share sales program (424B3, filed Mar 10, 2025)

For Pro members: 6 raises and their amounts, and the share count against a year ago.

Insiders

Chief Scientific Officer Johannes Jacob Pieter Kastelein sold 50,246 shares on Sep 30, under a planned sale. 19 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Michael Davidson buys or sells

For Pro members: every trade, and Michael Davidson’s 11 filings and quotes.

Get an alert when NAMS files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How NAMS ranks in Biotech

NAMS is #188 of 281 by Quality Score.

How NAMS ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	MXCTMaxCyte		Open for its score
	NAGENiagen Bioscience		Open for its score
	NBIXNeurocrine Biosciences		Open for its score
	NGENNervGen Pharma		Open for its score
188	NAMSNewAmsterdam Pharma	2/14	-3

When does NAMS report earnings, and what happens after?

Expected to report Wed Feb 17, before the open (in 100 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+12.5%-0.5%+5.2%

May 7Aug 5Nov 4

Reported	When	Gap	Reaction	5 days
Nov 4, 2026Before open	Before open	+11.9%	+5.2%	not yet
Aug 5, 2026Before open	Before open	-0.8%	-0.5%	+0.3%
May 7, 2026Before open	Before open	+6.6%	+12.5%	+21.8%

NAMS closed higher after 3 of its last 4 reports.

All 4 reports, and NAMS's Quality Score going into each

NAMS sales and profit by year

Sales and profit by year

Sales grew in one of the last three years, to $22.5M in 2025. It lost money in each of the four years.

NAMS has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NAMS, and all 14 on every stock.Get in free →

NAMS RSI on Nov 6: 38.2, below its 50-day and 200-day averages

Not scored

RSI 38.2, MACD below signal, below both averages. Not scored.13 readings

The deep dive on NAMS

What it does and how it makes money2 findingsAn operating loss of $226M in fiscal 2025, on $22.5M of sales.Annual report, filed Feb 18, 2026
Where it stands2 findingsFor Pro members2 findings on where NAMS stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades NAMS, for Pro members

6 more findings on NAMS, each with its source, for Pro members.

NAMS share count over time

4% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of NAMS outstanding, as filed
Shares outstanding	As of
119.5M	Aug 3, 2026
116.9M	Apr 29, 2026
115M	Feb 5, 2026
113.4M	Oct 31, 2025

Offerings, shelves, and splits of NAMS, from its filings
From its filings	Filed
Set up an at-the-market program for up to $250M of shares, about 11% of its market value	Mar 10, 2025
Registered shares for a later sale (S-3)	Feb 28, 2025
Raised $296.9M in a sale of shares, about 13% of its market value	Dec 13, 2024
Set up an at-the-market program for up to $150M of shares, about 7% of its market value	Aug 9, 2024

5 more offerings on file, for Pro members.

NAMS insider trades

One insider bought $227K across 1 filing, and one insider sold $41K across 1 filing, in the last 6 months. The newest:

BuyMichael H. Davidson$227KChief Executive Officerat $22.65 on Sep 14, filed Sep 15

BuyMichael H. DavidsonChief Executive Officer$227Kat $22.65 on Sep 14, filed Sep 15

NAMS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Michael H. DavidsonChief Executive Officer · 6 trades
Mayur Ian SomaiyaChief Financial Officer · 3 trades
Louise Frederika KooijChief Accounting Officer · 11 trades
Johannes Jacob Pieter KasteleinChief Scientific Officer · 8 trades
Robert William GunningVice President, Controller · no trades on file
Louis G. LangeDirector · 3 trades
John W. SmitherDirector · 1 trade
William LewisDirector · no trades on file

3 more officers and directors file at NAMS.

See insider trades by person

About NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

100 employeesNarrdennewamsterdampharma.com

What NewAmsterdam Pharma says it competes with

“The biopharmaceutical industry is characterized by intense competition and rapid innovation.”

From its annual report, SEC filing · Feb 18, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NAMS and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn NAMS's score around: 7 things
11 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 15Michael H. Davidson bought NAMS$226K at $22.65, filed Sep 15

Alerts are optional.

See NAMS's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: NAMS's Quality Score is -3 (Poor), #188 of 281 in Biotech. Insiders bought $227K and sold $41K in the last 6 months (Form 4).

What does NAMS's Quality Score say?

NAMS scores -3 today, which Breakaway calls Poor. It is #188 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 32% in 3 months, 14% under its 50-⁠day average. Cash lasts about 18 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NAMS's Quality Score?

NAMS scores -3 today, which Breakaway calls Poor (below zero). That is #188 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NAMS's -3.

Are insiders buying NAMS?

One insider bought $227K across 1 filing, and one insider sold $41K across 1 filing, in the last 6 months. The newest is Michael H. Davidson, Chief Executive Officer, who bought $227K on Sep 14. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.